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INTRODUCTION
Bone loss is highly prevalent in our CF population (70%) and is associated with                 
risk factors: age, low vitamin D levels, low BMI and CFRDM.1 The evidence that           
low BMD is a predictor of fracture risk is inconclusive and whilst there are some               
data to suggest that oral bisphosphonates 2,3 increase BMD, what remains
unclear is the clinical significance of bone loss we have documented is in our
centre.  We hypothesise that bone loss occurs in patients with risk factors
described above, and that treatment using the CF Trust Bone Mineralisation
Guidelines will result in improvement in BMD.  However, we present 4 case
studies which show that not all patients “fit this picture” and that treatment
does not always result in the predicted outcome.
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CONCLUSION
These 4 case studies illustrate  the diversity of presentation and variability in outcomes with or without treatment for bone 
loss.  Adherence to therapy and individual differences in response to treatment are hard to predict.   We conclude that 
detection and management of bone loss in CF continues to be challenging.  Individual treatment decisions should be 
based on individual measurements, as protocol-based decisions do not suit the circumstances of all individuals.
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Case study 1
o Male aged 37: DF 508 Homozygote, PI, 
FEV1 17%, BMI 20.4, CFRDM (on insulin), 
Vitamin D*23nmol/L, frequent 
exacerbations, referred for lung 
transplant.
o 1st DEXA: Z Scores -3.9 (LS), -2.4 (H) 
Treated with Alendronate 70mg orally 
weekly. 
o Rpt DEXA @ 2yrs Z Scores -2.7 (LS) -2.2 
(H), (FEV1 21% BMI 25.9, Vitamin D 
53nmol/L)
o Rpt DEXA @ 4yrs Z Scores -2.6 (LS), -2.0 
(H) (FEV1 16%, BMI 24.9, Vitamin D 
98nmol/L)
o Rpt DEXA @ 5.5yrs Z Scores -3.9 (LS), -
1.9 (H), (FEV15%, BMI 24.8 Vitamin D 
41nmol/L)
Summary Despite treatment for 5 yrs, no 
improvement in bone loss, however overall 
decline in health
Case study 2
o Female aged 43: DF508/unknown, PI, FEV1 
25%, BMI 17, CFRDM (no insulin) Vitamin D 
68nmol/L, frequent exacerbations, NG 
feeding
o 1st DEXA: Z Scores -0.4 (LS), -0.5 (H)
o No treatment (died 6 months post scan)
Summary No bone loss in patient with 
severe CF despite multiple risk factors.
Case study 3
o Male aged 39: DF508 Homozygote, PI, 
FEV1 31%, BMI 21.9, CRDM (on insulin), 
Vitamin D 82nmols/L
o 1st DEXA: Z Scores -0.3(LS), -0.7 (H)-
No treatment
o Rpt DEXA @3yrs Z Scores -0.3 (LS), -
0.6(H) FEV1 31%, BM1 22.2, Vitamin D 
53nmols/L
o now frequent exacerbations, referred 
for transplant.
Summary DEXA scan continues to be in 
normal range despite worsening health 
and falling Vitamin D levels.
Case study 4
o Male aged 48:DF508/5T-9T, PS, FEV1
100%, BMI 31.5, Vitamin D 25nmols/L,
o 1st DEXA: Z Scores -2.5(LS), -1.3(H) 
Treated with Alendronate 70mg orally 
weekly
o Rpt DEXA @ 2.5yrs Z Scores -2.7 (LS), 
-1.0 (H), (FEV1 101%, BM1 32.4,Vit D 
30nmols/L)
Summary Deterioration in DEXA scan at 
2.5yrs post Alendronate treatent, 
despite stable health in well patient 
with mild CF.
*Vitamin D measured as 25-OH Vitamin D 
(nmols/L range;25-170) LS=Lumbar Spine H=hip
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